Treatment patterns and survival in intermediate liver cancer
Part of Cancer clinical trials.
This study looks at how people with intermediate-stage liver cancer are treated in real life and how well they do over time. Researchers want to understand which treatments work best for this group so future patients can get better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- Your cancer is at intermediate stage (BCLC-B).
- Your liver function is fairly good (Child-Pugh A or B).
- You are able to be up and about (ECOG score 0 or 1).
- You have not had curative treatments like surgery, transplant, or ablation before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how bile duct and liver cancers change during treatment, to help doctors find the best therapies for patients. It is for people who are newly diagnosed or starting a new treatment.
This study reviews medical records of people diagnosed with hepatocellular carcinoma (liver cancer) between 2015 and 2023 to better understand how the disease progresses and how different treatments work. Your information helps researchers learn what care approaches work best for future patients.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
This study looks at how well different combinations of interventional procedures (like TACE) and systemic treatments (like targeted therapy or immunotherapy) work for liver cancer. It uses real-world data to find which combinations might be best for different patients.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
Hear when a new BCLC Stage B Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.